Rare Disease Report

VBP15 To Treat Duchenne Muscular Dystrophy - Clinical Trial Update

APRIL 22, 2015

In this interview, Eric Hoffman, PhD, president and chief executive officer of ReveraGen Biopharma, provides an update on the phase 1 and 2 studies either underway or planned for the use of VBP15 to treat patients with Duchenne muscular dystrophy.

For more information, click here.

Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.